Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients

World Journal of Biological Psychiatry

Volumn 11, Issue 2 PART 2, 2010, Pages 256-261

  Yoshimura, Reiji ^a   Ueda, Nobuhisa ^a   Hori, Hikaru ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Atypical antipsychotic drugs; Brain derived neurotrophic factor; Catecholamine metabolites; Schizophrenia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; HOMOVANILLIC ACID; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINERGIC SYSTEM; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HOMOVANILLIC ACID; HUMANS; LONGITUDINAL STUDIES; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; PIPERAZINES; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 77950807915     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970802309617     Document Type: Article

References (37)

1. Alter CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AK, et al. 1997. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389:856-860.
2. Buckley P, Pilai A, Evans D, Stirewait E, Mahadik S. 2007. Brain derived neurotrophic factor in first-episode psychosis. Schizophr Res 91:1-5.
3. Durany N, Micheal T, Zochling R, Boissl K, Cruz-Sanchez F, Riederer P, et al. 2001. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 52:79-86.
4. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-De-Abreu PS, Kapczinski F. 2007. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 420:45-48. (Pubitemid 46777098)
5. Guillain O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. 2001. BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization. Nature 411:86-89.
6. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. 2007. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 41:31-35.
7. Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, et al. 2000. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95:2514-2522.
8. Hori H, Yoshhimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, et al. 2007. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 22:21-27.
9. Jockers-Scherubl MC, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schurer F, et al. 2004. Brain-derived neurotrophic factor serum concentrations are increased in drug-nave schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 371:79-83.
10. Krieger K, Klimke A, Henning U. 2004. Antipsychotic drugs influence transport of the beta-adrenergic antagonist [3H]-dihydroalprenol into neuronal blood cells. World J Biol Psychiatry 5:100-106.
11. Li XM, Perry KW, Wong DT, Bymaster FP. 1998. Olanzapine increases in vivo dopamine and noradrenaline release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136:153-161.
12. Lommatzsch M, Zingler D, Schuhbaeck K, Schuhbaeck K, Schloetcke K, Zingler C, et al. 2005. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 26:115-123.
13. Maas JW, Hattox SE, Green NM, Landis DH. 1979. 3-Methoxy-4- hydroxyphenethyleneylglycol production by human brain in vivo. Science 205:1025-1027.
14. Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S, et al. 2007. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 68:512-517.
15. Meltzer HY, Stahl SM. 1976. Thee dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2:19-76.
16. Minegishi A, Ishizaki T. 1984. Determination of free 3-methoxy-4- hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric determination. J Chromatogr 311:51-57.
17. Nagaoka S, Iwamoto N, Arai H. 1997. First-episode neurolepticfree schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical response to haloperidol treatment. Biol Psychiatry 41:857-864.
18. Pirildar S, Gonul AS, Taneli F, Akdeniz F. 2004. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Progr Neuro-Psychopharmacol Biol Psychiatry 28:709-713.
19. Podusto JF, Curran GL. 1996. Permeability at the blood-brain and blood nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol Brain Res 36:280-286.
20. Shimuzu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakari C, et al. 2003. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70-75. (Pubitemid 36776725)
21. Snyder SH. 1976. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 133:197-202.
22. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. 2000. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 5:293-300.
23. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. 2005. Deceased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 382: 27-32.
24. Thoenen H. 1995. Neurotrophins and neuronal plasticity. Science 270:593-598.
25. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. 2000. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110:249-257.
26. Umene W, Yoshimura R, Hori H, Nakano H, Sugita A, Shimono M, et al. 2007. Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea. World J Biol Psychiatry 26:1-4.
27. Weickert CS, Hyde TM, Lopska BK, Herman MM, Weinberger DR, Kleinman JE. 2003. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8:592-610.
28. Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM, et al. 2005. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 10:637-650.
29. Westerink BHC, De Boer P, Vries JB, Kruse GG, Long SK. 1998. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol 361:27-33.
30. Yamamoto K, Hornykiewicz O. 2004. Proposal for a noradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:913-922.
31. Yeung PK, Buckley SJ, Pedder SC, Dingemanse J. 1996. Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci 85:451-453.
32. Yoshimura R, Yanagihara N, Hara K, Terao T, Nakamura J, Ueno S, et al. 2000a. Inhibitory effects of clozapine and antipsychotic drugs on noradrenaline transporter in cultured bovine adrenal medullary cells. Psychopharmacology 149:17-23.
33. Yoshimura R, Nakamura J, Ueda N, Terao T. 2000b. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels and clinical improvement. Int Clin Psychopharmacol 15:175-180.
34. Yoshimura R, Ueda N, Shinkai K, Nakamura J. 2003. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 18:107-111.
35. Yoshimura R, Nakamura J, Shinkai K, Ueda N. 2004. Clinical response to antidepressants treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry 28:611-616.
36. Yoshimura R, Shinkai K, Toyohira Y, Ueno S, Yanagihara N, Nakamura J. 2005. Effects of zotepine and olanzapine on noradrenaline transporter in cultured bovine adrenal medullary cells. Hum Psychopharmacol 20:477-484. (Pubitemid 41489459)
37. Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, et al. 2007. Treatment with risperidone increased plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 31:1072-1077.